Lupus Interventional Clinical Trials Program

Addressing the unmet need to develop safe, effective, and long-lasting lupus treatments.

The goal of the Hospital for Special Surgery (HSS) Lupus Interventional Clinical Trials Program is to advance toward the development of innovative therapies and treatments that will improve the quality of life of lupus patients. At the same time, we strive to reduce hospitalizations and prevent complications related to treatment or disease activity. Our goal is to maximize patient wellbeing by helping them return to everyday activities one step at a time.

We believe that the objectives of advancing lupus care are best achieved through novel, cutting-edge research. In addition to supporting the observational and exploratory research that occurs at HSS (research not involving investigational drugs), the HSS Lupus Clinical Trials Program manages numerous interventional trials for novel therapies.

Within the Lupus and APS Center of Excellence, the HSS Lupus Clinical Trials Program collaborates closely with physicians and social work across the hospital’s rheumatology department. We work closely together with other subspecialties (ie nephrology and oncology) from New York Presbyterian Hospital – Weill Cornell as well as Memorial Sloan Kettering Cancer Center in some of our studies as necessary. Additionally, the HSS Lupus Clinical Trials Program is an active site of The Lupus Clinical Investigators Network (LuCIN) a lupus clinical trials network made up of 57 of the most prestigious academic research medical centers throughout North America, and the Lupus Nephritis Trials Network (LNTN), a worldwide organization that brings researchers together with the shared goal of improving outcomes for patients with lupus nephritis.

Our team takes pride in the way we conduct clinical trials. We prioritize safety of our patients, and we conduct trials in compliance with federal and institutional regulations.